Medical Design Briefs - January 2024 - 7

businesses, and highest growth businesses.
In its established market leaders
- including cranial and spinal
technologies, surgical, and cardiac
rhythm management - Medtronic
has been performing strongly. These
businesses made up just under half
of its revenue and grew organically 6
percent with strengths in hernia and
electrosurgery. Cardiac rhythm management
grew 4 percent, with notable
success in cardiovascular diagnostics
and cardiac pacing.
Key product highlights showcased
growth in surgical and cardiac rhythm
management segments, with strategic
approvals such as the FDA approval for
the Aurora EV-ICD™ system marking a
pivotal moment. The Aurora EV-ICD
system provides the life-saving benefits
of traditional ICDs while avoiding certain
risks because its lead (thin wire) is
placed outside the heart and veins. Patients
implanted with the Aurora EV-ICD
system have defibrillation, antitachycardia
pacing (ATP), and backup pacing
therapies available to them via a single
implanted device that is similar in size,
shape, and longevity to traditional ICDs.
The system approval also includes proprietary
procedure implant tools.
In synergistic and highest growth
businesses, growth was seen particularly
in cardiac ablation solutions and structural
heart segments. Arctic Front was
the first anatomical balloon technology
using cryo energy on the market. The
balloon featured four jets. Arctic Front
Advance™ features improved temperature
uniformity with EvenCool™ cryo
technology (8 jets), enabling more contiguous
lesions.
Medtronic's diabetes
business witnessed
its highest growth in 10 quarters,
with a 7 percent increase, attributing
success to the MiniMed™ 780G system.
The MiniMed 780G includes Meal Detection™
technology that can automatically
deliver correction boluses of insulin
without any work needed from the patient,
as quickly as every 5 minutes. It includes
personalized glucose targets, and
the system automatically adjusts insulin
delivery all day and night to help prevent
highs and lows.
Medtronic raised its fiscal 24 organic
revenue growth guidance to 4.75 percent.
This reflects the company's momentum
and future pipeline, with future
growth drivers including the U.S. launch
of Hugo™ robotic system and the global
rollout of Evolut™ FX in Structural Heart.
technology megatrends like robotics
and artificial intelligence, " said Martha.
Large-scale functional improvements
are being executed in global operations,
supply chain, and quality. Capital
is being decisively allocated to programs
in fast, secular growth markets,
and R&D investments are focused on
technology megatrends like robotics
and artificial intelligence, he said.
Peering into Medtronic's Portfolio
Medtronic groups its portfolio businesses
in three categories: established
market leader businesses, synergistic
Medical Design Briefs, January 2024
Arctic Front Advance™ features improved temperature uniformity with EvenCool™ cryo technology (8 jets).
(Credit: Medtronic)
www.medicaldesignbriefs.com
7

http://www.medicaldesignbriefs.com

Medical Design Briefs - January 2024

Table of Contents for the Digital Edition of Medical Design Briefs - January 2024